Page last updated: 2024-10-26

dipyridamole and Respiratory Distress Syndrome, Newborn

dipyridamole has been researched along with Respiratory Distress Syndrome, Newborn in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Respiratory Distress Syndrome, Newborn: A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnold, P1
Hayden Smith, J1
Haynes, S1
Hasan, A1
Hamilton, JR1

Other Studies

1 other study available for dipyridamole and Respiratory Distress Syndrome, Newborn

ArticleYear
Use of dipyridamole for pulmonary hypertension following repair of total anomalous pulmonary venous drainage.
    Intensive care medicine, 2000, Volume: 26, Issue:1

    Topics: Dipyridamole; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Postoperative Complications; P

2000